menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu QYuns Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Licensing Agreement","leadProduct":"QX031N","moa":"IL-33\/TSLP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Jiangsu QYuns Therapeutics","amount2":1.0700000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":1.0700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu QYuns Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"4","companyTruncated":"Jiangsu QYuns Therapeutics \/ F. Hoffmann-La Roche"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu QYuns Therapeutics

    Menu

    Jiangsu QYuns Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu QYuns Therapeutics

                            China arrow
                            BOS Manchester
                            Not Confirmed

                            Jiangsu QYuns Therapeutics

                            China arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : QX031N

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Preclinical

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,070.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Roche Inks $1B Deal for Respiratory Bispecific from China

                            Details : Through the licensing deal, QX031N, an antibody targeting IL-33/TSLP, will advance the treatment of Chronic obstructive pulmonary disease (COPD).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $75.0 million

                            October 30, 2025

                            Lead Product(s) : QX031N

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Preclinical

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : $1,070.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth